Xu H - Search Results

1

MAFG-AS1 is a prognostic biomarker and facilitates prostate cancer progression.

Li P, Shi Y, Guo M, Xu H, Zhan M, Wang Z, Chen Y. Li P, et al. Among authors: xu h. Front Oncol. 2022 Aug 5;12:856580. doi: 10.3389/fonc.2022.856580. eCollection 2022. Front Oncol. 2022. PMID: 35992831 Free PMC article.

2

Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer.

Shen Y, Xu H, Long M, Guo M, Li P, Zhan M, Wang Z. Shen Y, et al. Among authors: xu h. Front Oncol. 2021 Nov 5;11:761643. doi: 10.3389/fonc.2021.761643. eCollection 2021. Front Oncol. 2021. PMID: 34804963 Free PMC article.

3

Serum Metabolic Profiling Identifies a Biomarker Panel for Improvement of Prostate Cancer Diagnosis.

Xu H, Chen J, He J, Ji J, Cao Z, Chen X, Xu Y, He X, Xu G, Zhou L, Wei X, Hou J, Wang Z, Yang B, Wang F. Xu H, et al. Among authors: xu g, xu y. Front Oncol. 2021 May 7;11:666320. doi: 10.3389/fonc.2021.666320. eCollection 2021. Front Oncol. 2021. PMID: 34026644 Free PMC article.

4

Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer.

Xu H, Chen Y, Gu M, Liu C, Chen Q, Zhan M, Wang Z. Xu H, et al. Metabolites. 2021 Nov 9;11(11):765. doi: 10.3390/metabo11110765. Metabolites. 2021. PMID: 34822423 Free PMC article. Review.

5

E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1.

Li P, Xu H, Yang L, Zhan M, Shi Y, Zhang C, Gao D, Gu M, Chen Y, Wang Z. Li P, et al. Among authors: xu h. Cell Death Dis. 2022 Jan 24;13(1):77. doi: 10.1038/s41419-022-04525-1. Cell Death Dis. 2022. PMID: 35075115 Free PMC article.

6

ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators.

Cai Z, Xu H, Bai G, Hu H, Wang D, Li H, Wang Z. Cai Z, et al. Among authors: xu h. Front Oncol. 2022 Aug 1;12:939784. doi: 10.3389/fonc.2022.939784. eCollection 2022. Front Oncol. 2022. PMID: 35978821 Free PMC article.

7

The function of oxytocin: a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer.

Xu H, Fu S, Chen Q, Gu M, Zhou J, Liu C, Chen Y, Wang Z. Xu H, et al. Oncotarget. 2017 May 9;8(19):31215-31226. doi: 10.18632/oncotarget.16107. Oncotarget. 2017. PMID: 28415720 Free PMC article.

8

The use of an oxidative stress scoring system in prognostic prediction for kidney renal clear cell carcinoma.

Wang X, Xu H, Guo M, Shen Y, Li P, Wang Z, Zhan M. Wang X, et al. Among authors: xu h. Cancer Commun (Lond). 2021 Apr;41(4):354-357. doi: 10.1002/cac2.12152. Epub 2021 Mar 3. Cancer Commun (Lond). 2021. PMID: 33657270 Free PMC article. No abstract available.

9

Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC).

Xu H, Liu Z, Gao D, Li P, Shen Y, Sun Y, Xu L, Song N, Wang Y, Zhan M, Gao X, Wang Z. Xu H, et al. Among authors: xu l. Mol Metab. 2022 May;59:101466. doi: 10.1016/j.molmet.2022.101466. Epub 2022 Feb 25. Mol Metab. 2022. PMID: 35219875 Free PMC article.

10

A prospective randomized controlled trial comparing the effect and safety of Piranha and VersaCut morcellation devices in transurethral holmium laser enucleation of the prostate.

Chen Y, Xu H, Gao D, Gu M, Liu C, Zhan M, Cai Z, Chen Q, Wang Z. Chen Y, et al. Among authors: xu h. Int Urol Nephrol. 2022 Nov;54(11):2977-2981. doi: 10.1007/s11255-022-03218-0. Epub 2022 May 21. Int Urol Nephrol. 2022. PMID: 35596886 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44,724 results

Search Page

Filters